iPhone Competition
advanced search

Welcome: Guest

log in

Women's Health Contraception

Publication Date March 2008
Publisher Life Science Analytics
Product Type Report
Pages 125
ISBN Number not applicable
Product Code LSA06368
Price

£800.00
approximately: $1,495 | €1,015

PDFBuy Now
PRINT £850 ($1,588 | €1,078)Buy Now
Order above formats by FAXOrder by FAX

Summary

Life Science Analytics', Ophthalmology and Optometry Glaucoma contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics' Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

  • Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
  • Keep track of your competitors and partners by better understanding their product pipeline.
  • Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
  • Maintain a critical competitive advantage.

Content

  • Recent Highlights and Changes
  • Upcoming Patent Expires by Therapy Area
    • Glaucoma Pipeline Overview
      • % of Projects (by Phase of Development)
      • No. of Projects by Phase of Development
      • Marketed Products vs. Pipeline Products
    • Company Overview - Pipeline Projects
      • Company Overview - Pipeline Projects
      • Top Companies in late stage Glaucoma Projects
      • Alcon Inc
      • Allergan Inc
      • Biovitrum AB
      • DAIICHI SANKYO COMPANY, LIMITED
      • Gene Signal International SA
      • InSite Vision Incorporated
      • NicOx S.A.
      • Pfizer Inc
      • Santen Pharmaceutical Co., Ltd.
      • Top Companies in early stage Glaucoma Projects
      • Aerie Pharmaceuticals, Inc
      • ACADIA Pharmaceuticals Inc
      • BioAxone Therapeutic Inc.
      • Allergan Inc
      • Ceregene, Inc
      • Cell Genesys Inc
      • Inotek Pharmaceuticals, Inc
      • Danube Pharmaceuticals, Inc.
      • Kissei Pharmaceutical Co., Ltd.
      • Inspire Pharmaceuticals Inc
      • Mimetogen Pharmaceuticals Inc.
      • Merck & Co Inc
      • Novartis AG
      • NOVAGALI PHARMA S.A
      • Othera Pharmaceuticals, Inc.
      • Opko Health, Inc.
      • Senju Pharmaceutical Co., Ltd.
      • Santen Pharmaceutical Co., Ltd.
    • Pipeline Revenue
      • Pipeline Revenue
    • Full Pipeline View
      • Pre Clinical Pipeline View
      • Phase I Pipeline View
      • Phase II Pipeline View
      • Phase III Pipeline View
      • Pending Approval Pipeline View
      • on the Market Pipeline View
      • Discovery/Development Pipeline View
About this Product
Delivery Details

PDF:Delivered by email usually within 4 to 8 UK business hours.
PRINT/CD-ROM:Despatched within 1 to 2 working days.

Ask a question about this product?

Recently Viewed Products
Women's Health Contraception

Industry Events

BioProduction 2008

28 Oct 08 to 29 Oct 08
Dusselfdorf, Germany
view summary >>

Agchemforum

29 Sep 08 to 02 Oct 08
Amsterdam, Netherlands
view summary >>

#